Table II.
Treatment courses of the sarcopenia and non-sarcopenia groups.
| Variable | Non-sarcopenia (n=81) | Sarcopenia (n=40) | P-value |
|---|---|---|---|
| Median relative dose intensity at 12 weeks (range) | |||
| Gemcitabine | 0.84 (0.11-1.0) | 0.73 (0.22-1.0) | 0.32 |
| Nab-paclitaxel | 0.80 (0.11-1.0) | 0.67 (0.11-1.0) | 0.26 |
| Dose reduction at GnP initiation, n (%) | 5 (6) | 4 (10) | 0.03 |
| Reason for GnP discontinuation, n (%) | |||
| Disease progression | 68 (84) | 30 (75) | 0.28 |
| Adverse events | 5 (6) | 5 (12.5) | 0.26 |
| Poor performance status | 2 (2) | 3 (7) | 0.20 |
| Patient's request | 3 (4) | 2 (5) | 0.77 |
| Conversion surgery | 3 (4) | 0 (0) | 0.20 |
| Secondary treatment, n (%) | 60 (74) | 29 (73) | 0.85 |
| Chemotherapy, n (%) | 54 (67) | 27 (68) | |
| Chemoradiotherapy, n (%) | 3 (4) | 1 (3) | |
| Conversion surgery, n (%) | 3 (4) | 0 (0) | |
| Others, n (%) | 0 (0) | 1 (3) |
The unpaired Student's t-test and Fisher's exact test were used for comparisons of treatment courses.